Headlands Technologies LLC Purchases 50,480 Shares of Novavax, Inc. (NASDAQ:NVAX)

Headlands Technologies LLC grew its position in Novavax, Inc. (NASDAQ:NVAX) by 1,084.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 55,137 shares of the biopharmaceutical company’s stock after purchasing an additional 50,480 shares during the quarter. Headlands Technologies LLC’s holdings in Novavax were worth $264,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Novavax by 9.3% in the third quarter. Vanguard Group Inc. now owns 11,551,476 shares of the biopharmaceutical company’s stock worth $83,633,000 after acquiring an additional 978,873 shares in the last quarter. SG Americas Securities LLC acquired a new position in Novavax during the fourth quarter worth $824,000. TSP Capital Management Group LLC lifted its stake in shares of Novavax by 15.0% in the fourth quarter. TSP Capital Management Group LLC now owns 1,111,700 shares of the biopharmaceutical company’s stock valued at $5,336,000 after buying an additional 145,350 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Novavax by 467.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,743 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 11,319 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Novavax by 31.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 99,314 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 23,715 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Novavax

In other news, Director James F. Young sold 7,500 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $14.09, for a total value of $105,675.00. Following the completion of the transaction, the director now directly owns 61,760 shares in the company, valued at $870,198.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Filip Dubovsky sold 47,312 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $13.90, for a total value of $657,636.80. Following the transaction, the insider now directly owns 38,953 shares in the company, valued at $541,446.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James F. Young sold 7,500 shares of Novavax stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $14.09, for a total transaction of $105,675.00. Following the sale, the director now owns 61,760 shares of the company’s stock, valued at $870,198.40. The disclosure for this sale can be found here. Insiders sold 62,312 shares of company stock valued at $866,212 over the last three months. Company insiders own 0.90% of the company’s stock.

Novavax Stock Down 2.4 %

Shares of NASDAQ NVAX traded down $0.40 during trading on Wednesday, reaching $16.04. 3,014,763 shares of the stock traded hands, compared to its average volume of 11,772,759. The company has a 50-day moving average of $14.05 and a 200-day moving average of $7.89. Novavax, Inc. has a 52-week low of $3.53 and a 52-week high of $23.86.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.01). The firm had revenue of $93.90 million for the quarter, compared to the consensus estimate of $71.32 million. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($3.41) earnings per share. On average, equities research analysts anticipate that Novavax, Inc. will post 0.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. B. Riley raised their price target on shares of Novavax from $11.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, May 23rd. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to a “neutral” rating in a report on Friday, May 10th. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Monday, May 13th. TD Cowen upped their target price on shares of Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a research note on Monday, May 13th. Finally, Bank of America boosted their target price on Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, June 14th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $19.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.